Great work as usual.
I would say the following list of diseases are potentially just the tip of the iceberg:
I would also suggest with our supply agreements with Bene and the complexity of the PPS molecule being copied it is IMHO unlikely that a bio-similar will be approved for use by the FDA for quite a while.
- OA
- CHIK-V
- RRV
- MPS
- HEART FAILURE
- ARDS
Not to mention the other drugs PAR are investigating for repurposing that we haven’t heard anything about.
My shares are locked away for the next 5 - 10 years.
iPPS and the not so Looney comparison, page-4
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.8¢ |
Change
0.013(5.10%) |
Mkt cap ! $91.06M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.5¢ | 25.0¢ | $140.4K | 545.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 160361 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 99769 | 3 |
View Market Depth
| Last trade - 14.08pm 12/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |